⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594420 | 0.80 | SLC22A6 (0.31) | — | |
| SCHEMBL25329509 | 0.76 | — | — | |
| SCHEMBL26306291 | 0.74 | KDM4E (0.45) | — | |
| SCHEMBL21787552 | 0.74 | LMNA (0.43) | — | |
| SCHEMBL10620895 | 0.72 | PTGS1 (0.31) | — | |
| SCHEMBL10231094 | 0.72 | LMNA (0.31) | — | |
| SCHEMBL14285109 | 0.72 | LMNA (0.31) | — | |
| SCHEMBL23267902 | 0.72 | LMNA (0.31) | — | |
| SCHEMBL743651 | 0.71 | — | — | |
| SCHEMBL3716505 | 0.71 | GABRR1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113181112-A | Neuroactive steroid solutions and methods of their use | 萨奇治疗股份有限公司 | 2021-07-30 | — | — | CN | claimed |
| US-20190008873-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | SAGE THERAPEUTICS INC (US) | 2019-01-10 | — | — | US | claimed |
| EP-3310394-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | Sage Therapeutics, Inc. (US) | 2018-04-25 | — | — | EP | claimed |
| WO-2016205721-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. (US) | 2016-12-22 | — | — | WO | claimed |
| US-12629360-B2 | Ophthalmic composition | Sydnexis, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4736853-A2 | DEGRADANT COMPOUND IN A MEDICAMENT | Visus Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12533374-B2 | Compositions and methods of use thereof | SYNEDGEN, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4236932-B1 | DEGRADANT COMPOUND IN A MEDICAMENT | VISUS THERAPEUTICS INC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20260000634-A1 | CARBACHOL FORMULATIONS TO ENHANCE ANTI-PRESBYOPIA EFFECTS | HERCULES CAPITAL, INC., AS AGENT | 2026-01-01 | — | — | US | disclosed |
| US-20250276038-A1 | HISTATIN COMBINATIONS AND METHODS FOR TREATING OR INHIBITING CELL LOSS | HERCULES CAPITAL, INC., AS AGENT | 2025-09-04 | — | — | US | disclosed |
| US-20250275983-A1 | D2O STABILIZED PHARMACEUTICAL FORMULATIONS | Sydnexis, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-20250255810-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2025-08-14 | — | — | US | disclosed |
| WO-2017156103-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2016205721-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016196367-A1 | D2O STABILIZED PHARMACEUTICAL FORMULATIONS | Sydnexis, Inc. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20160339007-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2016-11-24 | — | — | US | disclosed |
| WO-2016172712-A2 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-9421199-B2 | Ophthalmic composition | Sydnexis, Inc. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160009705-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2016-01-14 | — | — | US | disclosed |
| US-20150366854-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2015-12-24 | — | — | US | disclosed |